MiNK's Off-the-Shelf Cell Therapy Moves to the ICU: Ukraine Trial, Brazil Access, and a Stock on the Cusp
agenT-797 pivots from oncology to critical illness, with a paid named-patient program and a randomized Phase 2 now recruiting in war-torn Lviv.
INKT · Earnings Call · 2026-08-13
A Cell Therapy for the ICU
MiNK Therapeutics (INKT) is a tiny biotech with a singular asset: an allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapy, agenT-797. The company has spent years testing it in solid tumors, with mixed results. But the Q2 2026 report makes clear the strategic pivot is now unmistakable: “We moved agenT-797 into a randomized phase two study in patients with acute lung injury and ARDS.” — Jennifer Buell, Chief Executive Officer · 2026-08-13 The CEO, Jennifer Buell, frames this as the logical culmination of the platform's biology — iNKT cells that "read the tissue environment" and restore immune regulation. The market has taken notice only slightly: the stock is up ~10% over the last 90 days, but remains 94% off its 2021 peak. This quarter's developments could be the start of a real reversal. The randomized Phase 2 (C1300-02) is now active, with the first patient dosed within days of Ukrainian Ministry of Health authorization, in Lviv, during an active conflict. The setting is not incidental. conflict zones and the rising threat of hospitals in Europe being infiltrated by pan-resistant pathogens are central to the company's thesis. As Dr. Terese Hammond, Head of Development, noted in the Q&A, the patients in Ukraine are arriving with multidrug-resistant organisms before they've even been in the hospital 24 hours — a pattern she does not see in her own ICU in Central California. The trial is designed as a 1:1 randomized placebo-controlled study, but the company is already talking to the FDA about a seamless Phase 3 design, with 28-day mortality as the primary endpoint. The run-in cohort of 10 patients is nearly complete, and early data from the first two patients — both with severe ARDS and pan-resistant infections — showed 28-day survival, improved oxygenation, and resolution of ARDS, with no major safety signals. “In our trial, we reported that our patients were alive and without fever at day 28.” — Jennifer Buell, Chief Executive Officer · 2026-08-13 The company is careful to label these as early, non-randomized observations, but the mechanistic readouts (immune recovery, epithelial repair, vascular recovery) align with the clinical course. That coherence is what the CEO calls the "pattern you would predict if the mechanism is host-directed immune regulation."Brazil: A Paid Access Program
The second major announcement is the launch of MiNK's first international paid named patient access program, in Brazil, in collaboration with Orphan Drug Consultants. This is a departure from typical biotech de-risking. The program allows a treating physician to request agenT-797 for an individual patient with serious unmet need, subject to regulatory authorization. Critically, it is paid — MiNK receives payment per patient. While not a commercial launch, it establishes the logistics for cross-border cell therapy delivery: regulatory submissions, importation, pharmacovigilance. “Moving a cell therapy product reliably from inventory to an individual patient is where cell therapy programs typically fail.” — Jennifer Buell, Chief Executive Officer · 2026-08-13 The company reported that patients were treated just after quarter-end, with financials to be disclosed in Q3. This program is a meaningful step toward self-funding, especially given the company's cash position.While this is not a commercial launch, it is an important step in demonstrating that our existing inventory can support both clinical development and responsible physician directed access.